1. Special
Discounts
Available!
See pg. 7 for details
Source Funding. Forge Partnerships. Manage Relationships.
October 25-27, 2010 • The Ritz-Carlton, Laguna Niguel, CA
www.bionetworkus.com
Don’t Get Lost In The “Cattle Call” Of The Too-Big Industry Events. Spend
Quality Time With The Right People At BioNetwork.
• Gain insights from an unmatched speaker faculty and delegate base all eager to network and share knowledge
• Maximize over 14 hours of networking activities built into the agenda so that you can have meaningful
conversations over the course of three days
• 1:1 partnering software makes it easy for you to schedule private meetings with our speakers and delegates
before you get to the conference
• Onsite facebook allows you to put a face to a name while at the conference. That way you can easily pinpoint
who you want to speak with, instead of sifting through a sea of nametags
Top Speakers You Will Meet At BioNetwork:
Martin Reeves Ellen A. Lubman Robert Bagdorf
Vice President, Business Strategic Transactions Group Vice President, Worldwide
Development Bristol-Myers Squibb Business Development
Cephalon Pfizer Inc.
James Schaeffer
Gregg Talbert Executive Director, Worldwide David Donabedian
Managing Director, Mergers and Licensing and External Research Vice President, Strategic
Acquisitions, Corporate Finance and Merck Alliances, US CEEDD
Investment Banking (CFIB) Group GlaxoSmithKline
Chris Seaton
Eli Lilly
Senior Vice President, Global Kimberly Rogers
Robert Wills Transactions Vice President, Technology
Vice President Alliance Management, Bayer Healthcare Assessment
Pharmaceuticals Group Pharmaceuticals Allergan
Johnson & Johnson
PLUS - 2 Full Afternoons Of The Perfect Pitch – Biotech Investment Challenge!
In this groundbreaking session, 4 Biotechs will be given the opportunity to present their “perfect pitch” to our audience of potential
partners and investors as well as to our panel of experts who will provide them with invaluable feedback to strengthen their pitches.
Sponsors: Organized by:
REGISTER Call: 1-888-482-6012 or 1-646-200-7530 Fax: 1-646-200-7535
NOW! Email: bionetwork@wbresearch.com Web: www.bionetworkus.com
2. New And Improved Networking Opportunities Improved One-To-One Private
We make sure that you meet the people you came to see. Partnering Technology!
Onsite Facebook
Tired of sifting through a sea of name tags to find the person you want to meet? Upon check-in, the
• Internal messaging capability
BioNetwork team will be taking photos of all speakers and attendees so that you can easily spot the person • Scheduling blocking function
you wish to network with. • Personalized meeting requests designed to avoid
spam filters
Onsite Message Board
Placed in a central location by the registration area, the onsite message board allows you to leave notes for
• Conference agenda accessible through partnering
speakers or attendees that you are looking to connect with while at BioNetwork West. software
Schedule Meetings Before You Arrive! You have the opportunity to reserve the One-To-One
These pre-arranged rooms are available to be booked for 30 minute time blocks. 6 weeks out from Private Partnering Rooms for all three days of
BioNetwork West 2010, you will receive a password allowing you to schedule One-To-One Private BioNetwork West where you can privately discuss the
Partnering Rooms online. On our website you will find a list of registered attendees along with their contact specifics of your companies, your goals, and your
details (viewable at their discretion), a brief description of their companies and partnership aspirations and a compounds.
timetable of available meeting rooms. Upon receiving an accepted invitation from a potential partner, you *To view Who You Are Going To Meet At
will be able to schedule a private partnering room. Please contact Sarah Cascone with any questions BioNetwork, please visit the website
regarding the one-to-one partnering site at sarah.cascone@wbresearch.com or 646-200-7497. www.bionetworkus.com.
Conference Day 1 Monday, October 25, 2010
7:45 Networking Breakfast For All Attendees 11:00 Case Study: BMS And Allergan Global Agreement For
Conference Registration Sponsored By: Investigational Neuropathic Pain Medicine
Tim Herpin
8:30 Chairperson’s Opening Remarks Director, Search and Evaluation, Strategy,
Alliances and Transactions
8:45 Panel Session: Assessing The Deal-Making Landscape For 2010 - Bristol-Myers Squibb
A Reflective Look At The Deals Done This Past Year
Kimberly Rogers
Martin Reeves Vice President Technology Assessment
Vice President Business Development Allergan
Cephalon
This case study will look at the recent deal between BMS and Allergan for
Jim Hattersley Allergan’s experimental therapy for neuropathic pain. This session will look into
Vice President Corporate Business Development the strategic considerations behind the partnership from both BMS and
Sun Pharmaceutical Industries, Inc. Allergan's perspectives and delve into the steps and timelines of the partnering
Paul Darling process, the due diligence experience, and the status of the relationship today.
Principal
ZS Associates 11:40 Panel Session: Securing Funding In A Dry Market - The Industry
John Hebert Has Changed, Have You?
Associate Director, Corporate Development Mark Benedyk
Genzyme Head
Much has happened in the pharmaceutical space in the past year. Now is the The Pfizer Incubator LLC
perfect time to get a read on how the industry fared in 2010. This opening Matthew Q. Reber
panel session will analyze important developments in 2010 and its impact on Vice President
the industry on a larger scale: Outlining major deals in 2010; evaluating Cowen Healthcare Royalty Partners
financing in 2010; updates on the IPO window; Increase in foreign companies Matthew W. Kalnik, PhD
buying into the US market and who’s partnering with whom? Senior Vice President, Strategic Planning and Business Operations
Nabi Biopharmaceuticals
9:30 Panel Session: Industry Outlook - What Will The Pharma Space
Look Like In 5 Years? Henry Skinner, PhD
Managing Director
Chris Seaton Novartis Venture Funds
Senior Vice President, Global Transactions
Bayer HealthCare Pharmaceuticals With limited opportunities in IPO and traditional forms of funding dried up, the
market has had to employ creative methods of financing. This session will look
Robert Bagdorf at the new financing models currently being used in the pharmaceutical
Vice President, Worldwide Business Development industry: Corporate alliances, grants and government contracts; Monetizing
Pfizer Inc. assets in your portfolio to raise capital; Assessing international licensing options;
Executive Speaker and Panel Moderator Utilizing partnering as a means to gain capital.
Campbell Alliance
12:25 Networking Lunch For All Conference Attendees
In the wake of healthcare reform, the economic recession, industry
consolidation and the patent cliff the pharmaceutical space has seen Sponsored by:
considerable changes that will only continue. This session will look at the
pharmaceutical industry outlook and provide predictions for what we can 1:35 Case Study Part 2: Merck/Schering Plough Merger
expect in the coming years: impact of the healthcare reform on R&D and BD;
effects of industry consolidation; how will big Pharma offset the negative James Schaeffer
impact of dwindling pipelines. Executive Director, Worldwide Licensing and External Research
Merck
10:15 Refreshment Break And Networking Opportunity Following up on the case study delivered at the BioNetwork East conference in
March 2010, Dr. Jim Schaeffer joins us at BioNetwork West to continue the
story of the merger of two giants in the industry – Merck and Schering Plough.
Jim will share the process used during the integration and will share significant
2 Call: 1-888-482-6012 or 1-646-200-7530 Fax: 1-646-200-7535 Email: bionetwork@wbresearch.com Web: www.bionetworkus.com
3. progress of the New Merck, the resulting pipeline, current partnership interests, The panelists will then have a chance to confer and choose “the perfect pitch”
and finally, the next steps for the New Merck and your partner of choice. which will be presented at the awards ceremony cocktail reception immediately
following the afternoon’s presentations.
2:15 IP/Regulatory Update – The Pathway For BioSimilars Panel of Experts
Len Smith David Donabedian
Principal Intellectual Property Counsel Vice President, Strategic Alliances, US CEEDD
Medicis Pharmaceutical Corporation GlaxoSmithKline
It is no surprise that the healthcare reform bill was passed this spring. What is Fred Aslan
uncertain, however, is how pieces of this legislation will end up affecting the Vice President
Pharma space. This session will look at how the new pathway works from the Venrock
“biosimilars” vs. innovators perspective and how the availability of the pathway Kim Kamdar
might relate to deal making in the future. Principal
Domain Associates LLC
2:50 Refreshment Break And Networking Opportunity
3:30-3:50 Biotech #1 Presentation
3:30 The Perfect Pitch: Biotech Investment Challenge 3:50-4:10 Biotech #2 Presentation
4:10-4:30 Biotech #3 Presentation
Presented by: 4:30-4:50 Biotech #4 Presentation
Thomas Abbott 4:50-5:30 Feedback From Our Panel Of Experts
President
i3 Pharma Informatics *For more information on how you can participate in the Biotech Investment
Challenge, please contact Mimi Fox at 416-597-4808 or email
In this groundbreaking session, 4 Biotechs will be given the opportunity to mimi.fox@wbresearch.com
present their “perfect pitch” to our audience of potential partners and
investors as well as to our panel of experts. 5:30 Awards Ceremony And Cocktail Reception For All Attendees
Here’s how it works: Presented by:
Each Biotech will give a 20-minute company presentation. Then our panelists,
VCs and Investment Banks will give their feedback on the strengths of the The “Perfect Pitch” Awards Ceremony and Cocktail Reception will be held directly
pitches just heard, highlighting the portions of the presentations that piqued following this afternoon’s Biotech Investment Challenge. The award, presented
their interest. This will give the presenting companies, as well as the audience, by i3 Pharma Informatics and our panel of expert judges, will be given to the best
insight into what sparks the interest of potential partners and investors. This company pitch heard in the afternoon’s session. Join all conference attendees to
session is a must attend for Pharma, Biotechs, and the investment community. hear who our panel of experts have chosen as the “Perfect Pitch” for 2010.
Conference Day 2 Tuesday, October 26, 2010
7:45 Networking Breakfast For All Attendees Kris Ford
Conference Registration Sponsored By: Vice President Business Development
Intelliject
8:30 Chairperson’s Opening Remarks This case study will explore the recent deal between sanofi-aventis and Intelliject
Jeff Totten from each side's perspective. This session will discuss the motivations behind the
Vice President partnership and include the following: 1) Brief company overview, 2) Product
Dean & Company overview, 3) Deal scope & terms, 4) Strategic considerations that led to the idea,
5) For s-a, why IJ & this deal; for IJ, why s-a & this deal, 6) The process, 7) Update
8:45 The Morning After - Ensuring Partnerships Work In The Harsh on the status of the relationship today, 8) Lessons learned.
Reality Of Daylight
Robert Wills
10:25 Refreshment Break And Networking Opportunity
Vice President Alliance Management, Pharmaceuticals Group
Johnson & Johnson
11:10 Hearing From The Little Guy - Spotlight On Small Biotechs
Year after year, we hear from Big Pharma on what they look for in potential
David Donabedian partners. But partnering is a two-way street. These panel sessions will bring
Vice President, Strategic Alliances, US CEEDD together representatives from biotech companies and Big Pharma companies to
GlaxoSmithKline offer their insight on the following:
Laura Pierce Part 1- Defining The Difficulties Small Companies Face In Finding
Vice President, Alliance Management A Partner In Big Pharma
Bayer HealthCare Pharmaceuticals
John Mendlein
Alison Shurell Former CEO
Vice President, Product Marketing Adnexus Therapeutics
Intralinks
Matthew Meyer
Troy Windt Vice President Business Development
Senior Director, Corporate Development Cerimon
Upsher-Smith
This panel session will highlight the problems small Biotechs face when trying to
Maintaining relationships to work efficiently and effectively over time is traverse the big Pharma partnering market. Panelists will share their insights on
paramount in a successful partnership. This session will examine the role of the following: 1) What is the follow up process like for inquiries with big Pharma
the alliance management function in today’s partnering landscape. and how can it be improved?; 2) Outlining the process for finding the
• Pinpointing specific examples of the benefits realized through effectively appropriate person withi your therapeutic area: How easy is the process? What
managing your relationships could be changed? and 3) Highlighting other areas of this process that pose
• Measuring the success of an alliance- outlining the metrics to gauge problems for small companies
effectiveness
• Providing the new team with a secure and neutral platform for information 11:50 Part 2- In A Competitive Bidding Process - What Do Small
sharing and collaboration to ensure open communication throughout the Companies Look For In A Big Pharma Partner?
life of the partnership
Katrine Bosley
CEO
9:45 Case Study: Sanofi-Aventis And Intelliject - North American Avila
License For A Novel Epinephrine Auto-Injector
Jason Rhodes
Thomas Wiatrowski
Executive Vice President and Chief Business Officer
Director, U.S. Business Development
Epizyme Corporation
Sanofi-Aventis
Sponsors: 3
4. It’s true that in most cases big Pharma has its pick of biotech companies. But Denise McGinn
in a competitive bidding process, this is not the case. This session will bring Vice President of Licensing & New Business Development,
together representatives from small Biotechs that have gone through a Pharmaceuticals Group, Johnson & Johnson
competitive bid to better understand the following: This case study will discuss the co-promotion of Velcade in Japan from the
• Identifying the due diligence process for a small company perspectives of both J&J and Takeda. From the strategic considerations that led to the
• What attributes are important in a big Pharma partner? idea, to the developing evaluations and steps that led to the negotiations, to the due
diligence experience, the deal signing and closing, and the status of the relationship
12:30 Networking Lunch For All Conference Attendees today. What was in it for Takeda? For J&J? What “lessons learned” were captured?
Sponsored By:
3:00 Refreshment Break And Networking Opportunity
1:40 Part 3 - BIG PHARMA Perspective: Defining The Difficulties
Small Companies Face In Finding A Partner In Big Pharma 3:30 The Perfect Pitch: Biotech Investment Challenge
Ellen A. Lubman In this groundbreaking session, 4 Biotechs will be given the opportunity to present
Strategic Transactions Group their “perfect pitch” to our audience of potential partners and investors as well as to
Bristol-Myers Squibb our panel of experts.
Yael Weiss Panel of Experts
Director, Licensing & External Research - West Coast Gregg Talbert
Merck Research Laboratories Managing Director, Mergers and Acquisitions, Corporate
Jack Tupman Finance and Investment Banking (CFIB) Group, Eli Lilly
Vice President, Corporate Business Development Frank Stokes
Eli Lilly and Company Managing Director
Understanding the challenges small biotechs face in gaining the partnership of R.W. Baird
Big Pharma, it is important to also understand what Big Pharma expects and 3:30- 3:50 Biotech #1 Presentation
needs from new partnerships. This panel provides important insights to 3:50- 4:10 Biotech #2 Presentation
provide you with a Big Pharma perspective in building and sustaining 4:10- 4:30 Biotech #3 Presentation
breakthrough partnerships. 4:30- 4:50 Biotech #4 Presentation
4:50- 5:30 Feedback from our panel of experts
2:20 Case Study: J&J / Takeda Co-Promotion For Velcade In Japan *For more information on how you can participate in the Biotech Investment
Kyle D. Kuvalanka Challenge, please contact Mimi Fox at 416-597-4808 or email
Vice President mimi.fox@wbresearch.com
Millenium: The Takeda Oncology Company
5:30 Awards Ceremony And Cocktail Reception For All Attendees
Conference Day 3 Wednesday, October 27, 2010
7:45 Networking Breakfast For All Attendees 10:00 Panel Session: Understanding The VC Due Diligence Process When
Conference Registration Sponsored By: Deciding On Investing In A Company
Howard D. Palefsky
8:30 Chairperson’s Opening Remarks Managing Director
Montreux Equity Partners
9:00 Case Study: Compare And Contrast Two Co-Promotion Deals:
Late Stage “Ready To Launch” vs. Early Stage Fred Aslan
Vice President
Jack Tupman Venrock
Vice President, Corporate Business Development
Eli Lilly and Company Kim Kamdar
Principal
Roger Graben Domain Associates LLC
Senior Vice President, Operations & Business Development
Kowa Pharmaceuticals America For small biotech companies, VC investment is critical to funding R&D projects in
their pipeline. With the market for investment as it is, the VC capital is not as free
Blake Salisbury flowing as it once was. Therefore, it is now more critical than ever to have a firm
Director Corporate Business Development understanding of the due diligence process a VC conducts when evaluating a
Eli Lilly and Company company.
Michael A. Johnson
Director Corporate Business Development 10:45 Refreshment Break And Networking Opportunity
Eli Lilly and Company
11:30 Case Studies: Assessing The Impact Of The Emerging Markets On
In December of 2009, Lilly concluded two co-promotion agreements – one with The Global Pharmaceutical Space
Kowa Pharmaceuticals of America, for a new statin that had already been Daniel Bagi M.D.
approved in the US but not yet launched, and another agreement with Incyte Managing Director
Corporation, for an early stage new mechanism oral Rheumatoid Arthritis Riso Pharma Tech Inc.
compound. This case study will include comments/discussion from the senior
Part 1: Case Study BRIC (11:30-12:15)
negotiators from the companies as they compare and contrast the differences in
Part 2: Case Study: MENA (12:15-1:00)
the two deal transaction processes highlighting some of the challenges/
opportunities and solutions associated with the different negotiations. It comes as no surprise that the emerging markets will play an integral role in the
growth of the pharmaceutical industry. By conservative estimates, the E7 alone will
be spending over 100B annually on pharmaceutical products by 2020. This section of
the agenda will focus on trends in the emerging markets as well as highlight
companies that have successfully capitalized on these growth markets.
1:00 Networking Lunch For All Attendees
2:00 End Of BioNetwork 2010
4 Call: 1-888-482-6012 or 1-646-200-7530 Fax: 1-646-200-7535 Email: bionetwork@wbresearch.com Web: www.bionetworkus.com
5. About Our Sponsors
Upsher-Smith is constantly looking for strong and trusted Campbell Alliance is the leading management
partnerships through licensing, joint ventures, profit sharing, co- consulting firm specializing in the pharmaceutical and
development and co-marketing arrangements. Upsher-Smith has a biotechnology industry. The firm's clients include most
wide U.S. distribution network, experienced sales force and established customer of the world's top-20 pharmaceutical companies, as well as numerous emerging and
relationships within all customer segments. Looking to the future, Upsher-Smith is midsize firms. Campbell Alliance is organized into practice areas, each specializing in a
focused on: critical industry function: Brand Management, Business Development, Clinical
• Building our current product pipeline Development, Managed Markets, Sales, and Trade and Distribution. From its locations
• Co-promoting and acquiring women’s health products ready for commercialization in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston,
• Developing, in-licensing and acquiring CNS products focused primarily on treatments Philadelphia, New York City, Atlanta, and London, the firm serves clients throughout
for epilepsy & Parkinson’s disease. North America, Europe, and Japan. For more information on Campbell Alliance, please
Our vision is to become a leader in providing therapies that empower people suffering visit http://www.campbellalliance.com
from central nervous system (CNS) diseases to lead healthy, productive lives. Our focus
is simple: Advancing pharmacotherapy. Improving life™. EvaluatePharma® is the premier source for commercial
analysis in the pharma and biotech sector, delivering
Dean & Company is a strategy consulting firm with a exclusive, trusted insight into industry performance. For
unique mix of both traditional business strategy work and industry insiders and the investment sector, EvaluatePharma® supports value-enhancing
a range of investing activities for large corporations, business decisions with unrivalled proprietary insight.
technology start-ups, and equity funds. We work with senior executives to dramatically EvaluatePharma® sets new industry standards by providing consensus forecasts on
improve and sustain their company's performance. Dean & Company has an global drug sales. Our expertise and innovative approach has driven other pioneering
established, highly successful track record in generating actionable and quantifiable developments including Merge Company tool, Calendar of Events and interactive NPV
results for our clients in the Life Sciences. These include a number of the largest global Analyzer.
companies as well as emerging leaders in the Pharmaceuticals, Biotechnology, and But it's not just our expertise that sets us apart. The reliability of our data and depth of
Medical Devices & Technology industries. We additionally have developed specialized coverage provide clients with commercial insights simply not available anywhere else.
expertise in the Vaccines industry. The hallmark of our work in life sciences, as in other
industries, is our ability to deliver highly quantitative, analytic-driven solutions to Gerson Lehrman Group (GLG) manages the world’s leading expert
complex business problems and the development of practical, action-oriented network and provides software and services to support a marketplace for
recommendations and their associated measurable impact on the bottom-line. Our life expertise. GLG's unparalleled network of leading expert consultants,
sciences capabilities extend across the following industry challenges and issues: known as the GLG CouncilsSM, includes more than 175,000 subject
Licensing/Strategic Alliances/M&A Due Diligence, Portfolio/Life Cycle Management, matter experts and many key opinion leaders (KOLs) who educate and provide insight
Product Commercialization & Launch, Manufacturing & Distribution Strategy, to decision makers worldwide. Healthcare companies use GLG to accelerate business
Competitive Intelligence/Benchmarking, Marketing Strategy, Pricing & Reimbursement, development research and gather superior market intelligence. GLG’s expertise reaches
R&D Productivity. www.dean.com every sector of the healthcare industry, from the mid-sized and most specialized
organizations to some of the largest pharmaceutical, biotechnology, healthcare services,
IntraLinks® provides enterprise-class solutions which facilitate and medical device and supply companies in the world. Visit us at www.glgroup.com.
the secure, compliant and auditable exchange of critical
information, collaboration and workflow management inside i3 is a full-service, global contract research company providing
and outside the enterprise. Our on-demand solutions help you organize, manage, share clinical research services for biotech and pharmaceutical clients. i3
and track information, enabling you to accelerate your workflow, optimize your takes a 360-degree view of health care to help its global
business processes and realize new profit potential. Since 1997, IntraLinks has been pharmaceutical, biotechnology, and medical device clients bring safe and effective
used on critical business processes by more than 750,000 users from 90,000 products to market quickly and help demonstrate their value, leading to increased ROI
organizations worldwide, including 10 of the top 10 pharmaceutical companies and and better patient care.
hundreds of biotechs. IntraLinks counts 800 of the Fortune 1000 as clients, including i3’s Pharma Informatics combines unparalleled data assets, online tools, and scientific
enterprises such as AstraZeneca Pharmaceuticals LP, Bank of America, Deutsche Bank expertise to help you attain a clearer understanding of your products’ potential and
and the FDIC. For more information, visit www.intralinks.com. corresponding market dynamics—so you can make more rapid, informed decisions
throughout development and commercialization.
Over 25 years, ZS Associates has helped clients in more than 70 countries
measurably improve their results through our comprehensive expertise in Founded in 1876, Eli Lilly and Company is now the 10th largest
sales and marketing consulting, capability building and outsourcing. Our pharmaceutical company in the world. Lilly has steadfastly remained
clients include multinational, midsize and entrepreneurial companies around independent, but not isolated. Across the globe, Lilly has developed
the world, with a deep and long-standing emphasis on the healthcare sector, and the productive alliances and partnerships that advance our capacity to develop innovative
pharma/biotech sector in particular. Through our business development and licensing medicines at lower costs. Lilly is consistently ranked as one of the best companies in the
practice area, we support both large and small pharma/biotech companies with services world to work for, and generations of Lilly employees have sustained a culture that
ranging from strategic portfolio evaluation and business development strategy to values excellence, integrity, and respect for people. Lilly's global employees number
evaluation of specific potential partners and deals. ZS has more than 1,300 approximately 40,000, and our medicines are marketed in 143 countries. Lilly has major
professionals serving clients from 19 offices worldwide. www.zsassociates.com research and development facilities in eight countries and conducts clinical trials in
more than 50 countries. Lilly makes medicines that help people live longer, healthier,
Sanofi-Aventis, a leading global pharmaceutical company, more active lives.
discovers, develops, and distributes therapeutic solutions to
address the world’s expanding healthcare needs. We work to Symphogen is developing superior antibody therapeutics to help
prevent and treat the diseases that we know of today, as well as those we may face people with seri¬ous diseases. With its proprietary Symplex™
tomorrow. With approximately 100,000 dedicated professionals in more than 100 discovery and Sympress™ manufacturing platforms, the
countries, sanofi-aventis is devoted to advancing healthcare around the world. We are company captures the diversity and specificity of the natural
committed to maintaining the innovative approach to pharmaceuticals established by immune response in rationally designed recombinant antibody composi¬tions.
our parent company, headquartered in Paris, France. Our U.S. affiliate, with Symphogen is maturing a diversified pipeline of internal and partnered prod¬ucts
headquarters in Bridgewater, New Jersey, employs approximately 15,000 professionals across multiple indications including cancer and infectious disease. Its technologies and
located throughout the country. Sanofi-aventis, U.S. is a dynamic healthcare expertise within the antibody field have been validated through corporate partnerships
organization working to meet the needs of physicians and their patients. At sanofi- with pharmaceutical companies in the US, Europe, and Japan. Symphogen’s corporate
aventis, each and every day we work for what really matters: health .For more office is located in Lyngby, Denmark and employs 70 people. Symphogen’s US
information, visit www.sanofi-aventis.us subsidiary, Symphogen, Inc. is headquartered in Princeton, NJ.
SPONSORSHIP OPPORTUNITIES AVAILABLE
Don’t miss your chance to be in front of the top pharmaceutical and biotech companies in North America. If you are offering a solution, service, or technology
that will help companies improve research and development, search and evaluation, licensing, strategic alliances, due diligence, or simply want to show how
you are the partner of choice in fueling opportunities for increasing drug pipelines, contact Jodi Richter, Director of Sponsorship and Sales,
646-200-7485 or email jodi.richter@wbresearch.com.
Sponsors: 5
7. Registration Information
The Perfect Pitch: Biotech Investment Challenge Sponsorship Opportunities Available
Find out how you can sponsor BioNetwork 2010. Unlike huge industry
In these innovative sessions eight Biotechs will be given the opportunity to events, BioNetwork allows you to meet senior executives from different
present their “perfect pitch” to our audience of potential partners and Pharmaceutical and Biotech companies on a one-to-one basis. For
investors as well as to our panel of experts. sponsorship inquiries please contact: Jodi Richter, Director of
Sponsorship and Sales, 646-200-7485 or email
jodi.richter@wbresearch.com.
Each Biotech will give a 20 minute company presentation highlighting their
current projects. Then our panelists, consisting of big Pharma, VCs and
Investment Banks will give their feedback on the strengths of the pitches just
heard- highlighting the portions of the presentations that piqued their interest. Tell Us Who You Want To Meet At
This will not only give the presenting companies the platform to attract new
partners, but will also give the presenting companies, and audience alike, BioNetwork 2010!
insight into what sparks the interest of potential partners and investors. This If you're already registered or are planning to register for BioNetwork
session is a must attend for Pharma, Biotechs, and the investment community. 2010, tell us about five people you would like to meet at the event. We
will reach out to them on your behalf to get them registered. Once they
The panelists will then have a chance to confer and choose “the perfect pitch” register, we will notify you, so you can set up one-on-one meetings with
them onsite at BioNetwork.
which will be presented at the awards ceremony cocktail reception
immediately following the afternoon’s presentations. Send your list of names, including job title, company, phone and email
address to bionetwork@wbresearch.com or go to our website at
If your company is interested in joining one of the Investment www.bionetworkus.com and complete the online form.
Challenge afternoons, contact Mimi Fox at 416-597-4808 or email
mimi.fox@wbresearch.com! Spaces are limited so sign up today!
Hotel Information
Ritz Carlton Laguna Niguel
One Ritz Carlton Drive, Dana Point, CA 92629
Conference Pricing Tel. 949-240-2000
Fax. 949-240-0829
http://www.ritzcarlton.com/en/Properties/LagunaNiguel/Default.htm
Pricing Register & Pay Register & Pay Register & Pay
By 7/30/2010 To By 8/31/2010 To By 9/30/2010 To Experience genuine renewal at The Ritz-Carlton, Laguna Niguel. Situated
Get $600 Off Get $400 Off Get $200 Off Full Price atop a 150-foot bluff, this peaceful sanctuary soars above the standard
Laguna hotels with refined elegance, a graceful atmosphere and impeccable
service. Located halfway between Los Angeles and San Diego, the luxury
3 Day Conference $2,600 $2,800 $3,000 $3,200 oceanfront resort offers panoramic white-water views of the Pacific. The
Ritz-Carlton, Laguna Niguel is a luxury resort like no other.
Group Discounts Register & Pay Register & Pay Register & Pay BioNetwork has procured a special conference rate of $330.00 per
for Teams of 2 night (plus tax). To book your reservations, call the Ritz Carlton Laguna
By 7/30/2010 To By 8/31/2010 To By 9/30/2010 To
or More Niguel at 949-240-2000 or 1-800-241-3333 and identify yourself as a
Get $800 Off Get $600 Off Get $400 Off Get $200 Off BioNetwork attendee. Rooms are limited and are on a first come, first
served basis, so make your reservations as soon as possible. The discounted
3 Day Conference $2,400 $2,600 $2,800 $3,000 rate expires September 24th, 2010. After September 24th, rooms may still
be available, so inquire with the hotel if you have missed the cut off date.
PURCHASE SELECT AUDIO PRESENTATIONS* FROM THIS EVENT!
Airport Options
Can't make it to BioNetwork 2010 or worried that there is too much information to digest in a • John Wayne/Orange County Airport; SNA (25 minutes/23 miles)
few short days at the event? No need to worry. You can purchase select audio presentations to http://www.ocair.com/
share with your entire team. • Long Beach Airport; LGB (45 minutes/44 miles)
http://www.lgb.org/
Register for the event today and for an additional $250 gain access to select audio • Los Angeles International Airport; LAX (60 minutes/63 miles)
presentations from this event. Can’t attend? Purchase the CD-ROM only for $580 http://www.lawa.org/
*Presentations available are at the approval of conference speakers. Allow 3-4 weeks after event • San Diego Lindbergh Field Airport; SAN (75 minutes/67 miles)
date for shipping. http://www.portofsandiego.org/
Small Biotechs & University Pricing Available! For every registration received for Bio Network,
WBR will donate a portion of the registration fee to
Please inquire about discounted rates at bionetwork@wbresearch.com or contact Smile Train. For more information about WBR’s
Mimi Fox at mimi.fox@wbresearch.com, 416-597-4808 to learn more. involvement with Smile Train, please visit
bionetwork@wbresearch.com.
Please Note: Delegate Substitutions And Cancellations:
•
To secure your team discount, register online at www.bionetworkus.com or contact Bill Penney at •
You may substitute delegates at any time by providing reasonable advance
1-866-691-7771 or bpenney@wbresearch.com notice to WBR.
•
Team discounts must be booked and paid for at the same time. Team discounts do not apply to •
For any cancellations received in writing not less than thirty (30) days prior to
sponsoring or exhibiting companies or non pharmaceutical, biotech company. the conference, you will receive a 75% credit to be used at another WBR
•
All discounts are taken off the full conference price. No two discounts or offers can be combined. conference which must occur within one year from the date of issuance of
•
Payment is due in full at the time of registration. Your registration will not be confirmed until such credit. An administration fee of 25% of the contract fee will be retained
payment is received and may be subject to cancellation by WBR for all permitted cancellations.
•
For payment methods and to register now, please visit www.bionetworkus.com. •
There are no refunds given under any circumstances.
Sponsors: 7
8. 10386.005/GS
Special
Attention Mailroom: If undeliverable to addressee, this time
Discounts
Available!
See pg. 7 for details
sensitive information should be forwarded to the
Source Funding. Forge Partnerships. Manage Relationships.
VP of Business Development
October 25-27, 2010 • The Ritz-Carlton, Laguna Niguel, CA • www.bionetworkus.com
“I have always found the BioNetwork meetings very productive. Due to its more
535 Fifth Avenue, 8th Floor
intimate setting, it is very easy to meet with companies and share ideas. This setting
coupled with a well organized and professionally managed conference always
New York, NY 10017
delivers a positive experience.”
- Mark Dennish, Vice President, Business Development, Daiichi Sankyo
WBR
Don’t Miss These Exclusive Networking Opportunities
www.bionetworkus.com
“BioNetwork is a top tier biotech/pharma industry
executives with many strong partnering functions
Unique To BioNetwork:
conference, integrating business development
October 25-27, 2010
Development, Sun Pharmaceutical Industries, Inc.
Laguna Niguel, CA
- Jim Hattersly, Vice President, Corporate Business
The Ritz-Carlton,
- great venues & very productive results”
• 30+ private one-to-one meeting • 5 networking refreshment breaks
opportunities • 3 networking breakfasts
When registering please provide the code above.
• 23 interactive and educational panel
• 3 networking lunches
sessions and case studies presented
by executive level industry leaders • 2 rewarding cocktail receptions
Your priority booking code is:
• Biotech Research Presentations at • 1 essential opportunity to source
the Perfect Pitch: Biotech funding, forge partnerships, and
Investment Challenge manage relationships with the
decision makers in your industry
Sponsors: Organized by:
REGISTER Call: 1-888-482-6012 or 1-646-200-7530 Fax: 1-646-200-7535
NOW! Email: bionetwork@wbresearch.com Web: www.bionetworkus.com
9. Organized by:
Can’t make it to:
or afraid there is too
much information
to digest in just a
few days?
Get Access to hours of valuable This Session Content is available for a
sessions and take-ways anytime, fraction of the registration price.
anywhere... You can view and listen to the content when
Now you can view this outstanding conference you want, where you want and as many times
content on your PC or laptop with a CD-ROM that as you want.
puts you front and center at these informative
sessions. You'll hear our expert speakers as they And if you attend BioNetwork 2010, this
take you through the PowerPoint slides that Conference CD-ROM set is only $250!
illustrated their talks. (That’s a $580 value!)
This user friendly format allows you to:
• Gain valuable insight from your peers and
competitors in various Fortune 500 Industries VIP Package: $250
without leaving the office. (Select any package to attend the event
• Share with your colleagues at work. and for an additional $250 get the
• Stay up to date with the latest strategies, tactics conference CD ROM*)
and trends in your industry.
CD ROM ONLY: $580 *
Now you can share what you learnt at
BioNetwork 2010, with your colleagues. *Presentations available are at the approval of conference
Don’t leave them in the dark. Purchase the speakers. Not all presentations will be published. Allow 3-4 weeks
after event date for shipping.
CD ROM today!
